- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00906022
Self Expanding Nitinol Stent Versus Percutaneous Transluminal Arterial Angioplasty (PTA) With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication (EXPAND) (EXPAND)
EXPAND Study - Self Expanding Nitinol Stent Versus PTA With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication. A Prospective, Multi-center, Randomized Clinical Trail With Follow-up Investigations at 1, 3, 6, and 12 Months.
The clinical investigation is a prospective, international, multi-centre, randomized (1:1) trial with follow up investigations at 1, 3, 6 and 12 months. Patients will be randomized either to treatment with stenting with the Astron Pulsar SE (4 or 5 mm diameter) stent or to PTA with optional bailout stenting in case of PTA failure.
The primary objective of this study is to show clinical improvement in the outcome of patients with symptomatic critical limb ischemia or severe intermittent claudication (Rutherford 3, 4, 5) treated with the Astron Pulsar SE (4 or 5 mm diameter) in comparison with PTA or optional bailout stenting in case of PTA failure.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10365
- Gefässzentrum Berlin, Evangelisches Krankenhaus KEH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 50 years
- Patient has signed the patient informed consent.
- Patient is willing to adhere to the follow up time points and to follow the requirements during the study
- Patient has symptomatic critical limb ischemia or severe intermittent claudication classified as Rutherford category 3, 4 or 5.
- Stenotic (> 50%) or occlusive atherosclerotic disease of the infrapopliteal arteries below the radiographic level of the knee joint and above the level of the ankle (includes the peroneotibial trunk, anterior tibial artery, posterior tibial artery and peroneal artery, excludes the popliteal artery), as determined by pre-procedure intra-arterial DSA (preferred) or conventional angiography.
- Target (study) lesion to be treated is a de novo lesion (lesion ≤ 190 mm length). NOTE: Multiple or diffused lesion treatment is allowed as long as total lesion length ≤ 190 mm)
- Reference vessel diameter is between 2.5 and 4.0 mm.
- Target vessel: It must be possible to follow the vessel run-off to the foot and/or the wound area. NOTE: Patients with incomplete or abnormal anatomical run-off are NOT excluded. Important is to see that the there is a run-off to the foot and/or wound area even if collaterals are involved.
- Haemodynamically significant inflow stenoses of vessels above the knee were successfully treated before.
- Lesions must be crossed successfully with a guide wire and guide wire must be within the true lumen of the distal vessel.
Notes:
- Target vessel has to be defined; Target vessel = vessel with target lesion to be treated
- Target vessel: Multiple or diffused lesions with total length > 190 mm => inclusion criteria are NOT fulfilled
- NON-target vessel(s): haemodynamically significant lesion can be treated according to investigator's discretion
Exclusion Criteria:
- Patient refuses treatment.
- Patient is legally, physically or mentally unable to give consent.
- ABI / TBI measurement is impossible.
- Target lesion is pre-treated.
- Target lesion lies within or adjacent to an aneurysm.
- Acute thrombus present in the target limb.
- The reference vessel diameter is not suitable for available stent size (RVD < 2.5 and > 4.0 mm).
- Length of lesion requires more than one treatment device (lesion length > 190 mm)
- Hybrid technique (bypass surgery and peripheral intervention with PTA or stent during the same session) is not allowed. Note: Allowed is if the patient got a P1 or P3 bypass in a previous session and it is possible to treat a distal lesion through that bypass in a separate session. Time window between bypass surgery and planned intervention must be at least 30 days.
- Life-expectancy less than 12 months at the time of screening.
- Patient has a known allergy to heparin, aspirin, clopidogrel or other anticoagulant/ antiplatelet therapies, to nickel or contrast media or is unwilling to tolerate such therapies.
- Patient has bleeding diatheses
- Patient is currently enrolled in another investigational device or drug trial.
- Patient took part in another investigational device or drug trial within 3 months prior to screening.
- Patient is currently breast-feeding, pregnant or intends to become pregnant.
- Myocardial infarction without coronary revascularization < 6 months prior to screening and with coronary revascularization < 1 month prior to screening.
- Previous coronary or peripheral bypass surgery within 30 days prior to screening.
- Patient had a calculated creatinine clearance < 30 ml/min within 30 days prior to screening.
- Patient had a stroke or TIA within the last 6 months prior to screening.
- Patient had a major amputation of the target limb (defined as above the ankle) at the time of screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Astron Pulsar Stent
Device: Astron Pulsar Stent
|
Stenting with Astron Pulsar
|
Active Comparator: PTA alone
Device: Balloon angioplasty alone
|
Balloon angioplasty alone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of sustained clinical improvement at 12 months follow up. Sustained clinical improvement is defined as: Upward shift of at least +1 (for Rutherford category 3) or +2 (for Rutherford categories 4 and 5) on the Rutherford scale.
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
MAE rate, amputation rate, mortality rate, Maximum Walking Distance and Pain Free Walking Distance, Quality of Life, Binary restenosis rate, technical and device success, hemodynamic outcome
Time Frame: 6 and 12 months
|
6 and 12 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C0801
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Intermittent Claudication
-
Losordo, Douglas, M.D.UnknownPeripheral Artery Disease | Severe Intermittent ClaudicationUnited States
-
Mid and South Essex NHS Foundation TrustRecruitingPeripheral Arterial Disease | Claudication, IntermittentUnited Kingdom
-
Louis MessinaBioMarin PharmaceuticalRecruitingPeripheral Vascular Diseases | Peripheral Artery Disease | Claudication, IntermittentUnited States
-
University Hospital, AngersCompletedPeripheral Artery Disease | Claudication, IntermittentFrance
-
Palo Alto Veterans Institute for ResearchSociety for Vascular SurgeryWithdrawnPeripheral Artery Disease | Claudication, Intermittent
-
University Hospital, EssenStraub Medical AGUnknownPeripheral Arterial Disease | Claudication, IntermittentGermany
-
University Hospital, EssenUnknownPeripheral Arterial Disease | Claudication, IntermittentGermany
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity Hospital, Angers; Imperial College London; Sheffield Hallam UniversityCompletedIntermittent ClaudicationUnited Kingdom
-
Paradigm SpineCompletedIntermittent Neurogenic Claudication (INC) as a Result of Spinal StenosisNetherlands
-
Imperial College LondonTerminatedStandardised Claudication Treadmill TestUnited Kingdom
Clinical Trials on Astron Pulsar Stent
-
Biotronik, Inc.CompletedPeripheral Vascular Disease | Peripheral Artery DiseaseCanada, United States
-
Biotronik AGBiotronik, Inc.UnknownPeripheral Vascular Disease | Peripheral Artery DiseaseGermany, Belgium, Austria, Switzerland
-
Flanders Medical Research ProgramCompletedPeripheral Vascular Disease | ClaudicationBelgium, Germany
-
Medical University of ViennaUnknownStent Restenosis | Intimal HyperplasiaAustria
-
Fundacion para la Formacion e Investigacion Sanitarias...Not yet recruiting
-
Flanders Medical Research ProgramCompletedPeripheral Vascular DiseaseBelgium
-
Vienna General HospitalCompletedPeripheral Vascular Diseases | Intermittent Claudication | AngioplastyAustria
-
University of California, Los AngelesTiny Blue Dot Foundation; The Dana FoundationTerminatedBrain Injuries | Consciousness DisordersUnited States
-
Massachusetts General HospitalActive, not recruiting
-
Neurological Associates of West Los AngelesEnrolling by invitation